IC
OLMA icon

Inscription Capital’s Olema Pharmaceuticals OLMA Stock Holding History

Inscription Capital’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$228K Hold
15,273
– – 0.02% 577
2025
Q4 		$382K Buy
+15,273
New +$272K 0.04% 435

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Inscription Capital's OLMA Position: Q1 2026 in Review

Inscription Capital held its Olema Pharmaceuticals (OLMA) position steady in Q1 2026 at 15,273 shares worth $228K. The position accounts for 0.02% of the portfolio, ranked #577.

Inscription Capital first reported a position in OLMA in Q4 2025 and has held it in 2 quarters since. The position peaked at $382K in Q4 2025. 195 funds tracked by Wall St. Rank hold OLMA as of Q1 2026.

  • Inscription Capital held 15,273 shares of Olema Pharmaceuticals worth $228K as of Q1 2026.
  • Inscription Capital left its Olema Pharmaceuticals share count unchanged in Q1 2026.
  • Olema Pharmaceuticals made up 0.02% of Inscription Capital's portfolio in Q1 2026, its #577 holding.
  • Inscription Capital first reported a position in Olema Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Inscription Capital's Olema Pharmaceuticals position peaked at $382K in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2026.

Based on Inscription Capital's 13F filing for Q1 2026, filed 20 Apr 2026.